TY - JOUR
T1 - Smoking and colorectal cancer in lynch syndrome
T2 - Results from the Colon Cancer Family Registry and the University of Texas M.D. Anderson Cancer Center
AU - Pande, Mala
AU - Lynch, Patrick M.
AU - Hopper, John L.
AU - Jenkins, Mark A.
AU - Gallinger, Steve
AU - Haile, Robert W.
AU - LeMarchand, Loic
AU - Lindor, Noralane M.
AU - Campbell, Peter T.
AU - Newcomb, Polly A.
AU - Potter, John D.
AU - Baron, John A.
AU - Frazier, Marsha L.
AU - Amos, Christopher I.
PY - 2010/2/15
Y1 - 2010/2/15
N2 - Purpose: Lynch syndrome family members with inherited germline mutations in DNA mismatch repair (MMR) genes have a high risk of colorectal cancer (CRC), and cases typically have tumors that exhibit a high level of microsatellite instability (MSI). There is some evidence that smoking is a risk factor for CRCs with high MSI; however, the association of smoking with CRC among those with Lynch syndrome is unknown. Experimental Design: A multicentered retrospective cohort of 752 carriers of pathogenic MMR gene mutations was analyzed, using a weighted Cox regression analysis, adjusting for sex, ascertainment source, the specific mutated gene, year of birth, and familial clustering. Results: Compared with never smokers, current smokers had a significantly increased CRC risk [adjusted hazard ratio (HR), 1.62; 95% confidence interval (95% CI), 1.01-2.57] and former smokers who had quit smoking for 2 or more years were at decreased risk (HR, 0.53; 95% CI, 0.35-0.82). CRC risk did not vary according to age at starting. However, light smoking (<10 cigarettes per day) and shorter duration of smoking (<10 years) were associated with decreased CRC risk (HR, 0.51; 95% CI, 0.29-0.91 and HR, 0.52; 95% CI, 0.30-0.89, respectively). For former smokers, CRC risk decreased with years since quitting (P trend <0.01). Conclusions: People with Lynch syndrome may be at increased risk of CRC if they smoke regularly. Although our data suggest that former smokers, short-term smokers, and light smokers are at decreased CRC risk, these findings need further confirmation, preferably using prospective designs.
AB - Purpose: Lynch syndrome family members with inherited germline mutations in DNA mismatch repair (MMR) genes have a high risk of colorectal cancer (CRC), and cases typically have tumors that exhibit a high level of microsatellite instability (MSI). There is some evidence that smoking is a risk factor for CRCs with high MSI; however, the association of smoking with CRC among those with Lynch syndrome is unknown. Experimental Design: A multicentered retrospective cohort of 752 carriers of pathogenic MMR gene mutations was analyzed, using a weighted Cox regression analysis, adjusting for sex, ascertainment source, the specific mutated gene, year of birth, and familial clustering. Results: Compared with never smokers, current smokers had a significantly increased CRC risk [adjusted hazard ratio (HR), 1.62; 95% confidence interval (95% CI), 1.01-2.57] and former smokers who had quit smoking for 2 or more years were at decreased risk (HR, 0.53; 95% CI, 0.35-0.82). CRC risk did not vary according to age at starting. However, light smoking (<10 cigarettes per day) and shorter duration of smoking (<10 years) were associated with decreased CRC risk (HR, 0.51; 95% CI, 0.29-0.91 and HR, 0.52; 95% CI, 0.30-0.89, respectively). For former smokers, CRC risk decreased with years since quitting (P trend <0.01). Conclusions: People with Lynch syndrome may be at increased risk of CRC if they smoke regularly. Although our data suggest that former smokers, short-term smokers, and light smokers are at decreased CRC risk, these findings need further confirmation, preferably using prospective designs.
UR - http://www.scopus.com/inward/record.url?scp=76749132847&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=76749132847&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-09-1877
DO - 10.1158/1078-0432.CCR-09-1877
M3 - Article
C2 - 20145170
AN - SCOPUS:76749132847
SN - 1078-0432
VL - 16
SP - 1331
EP - 1339
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 4
ER -